Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Suspends Leo’s Actinic Keratosis Drug Picato

Also Limits Use Of High-Strength Estradiol Creams

Executive Summary

The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.

You may also be interested in...



Almirall Aims To Disrupt Actinic Keratosis Space With Klisyri

Helped by its convenient five-day dosing, the shortest of any topical treatment for the precancerous skin disease, the Spanish company believes Klisyri, already launched in the US, will become a popular alternative to current options for actinic keratosis.

EMA Stands Firm On Estradiol Cream Safety Measure After Doubts Over Impartiality

After a 14-year-old legal dispute, the European Medicines Agency has now repeated its safety review of high-strength estradiol creams for treating vaginal atrophy and says it stands by its original recommendation to place a limit on how long patients should use these products.

International Regulators Plan Roadmap For Collaborative RWE Studies

Experiences during the COVID-19 pandemic are expected to help identify future opportunities for regulatory cooperation on real-world evidence and avoid divergent decision-making for products including advanced therapies and personalized medicines.

Topics

Latest News
UsernamePublicRestriction

Register

PS141528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel